3:14 PM
 | 
Dec 21, 2018
 |  BC Extra  |  Company News

ZappRx, Genentech partner to speed patient access to specialty drugs

ZappRx Inc. (Boston, Mass.) will use its digital platform in partnership with Genentech Inc. to improve patient access to specialty drugs for idiopathic pulmonary fibrosis (IPF) with a possible expansion to include allergic asthma and chronic idiopathic urticaria (CIU).

Genentech markets Esbriet pirfenidone...

Read the full 200 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >